Clinical Research Directory
Browse clinical research sites, groups, and studies.
5 clinical studies listed.
Filters:
Tundra lists 5 Chemotherapy-induced Alopecia clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT06011525
Prevention of Alopecia in Patients With Localised Breast Cancer
The prevention of chemotherapy-induced alopecia (CIA) is still imperfectly managed in France. Strengthening the evidence base on the benefits of strategies to prevent CIA, based on robust methodologies, remains a prerequisite for better integration of appropriate supportive care for patients receiving chemotherapy. This research should provide new knowledge on the benefits of scalp refrigeration during anthracycline- and taxane-based chemotherapy in preventing ACI, for each of the 2 refrigeration techniques. In addition to effectiveness in preventing ACI, quality of life, self-image and satisfaction with care will be assessed by patients during and after chemotherapy. The medico-economic aspects will also be assessed for each of the two refrigeration modalities. The results of the various proposed assessments will be used to guide the choice between these two techniques for preventing ACI.
Gender: FEMALE
Ages: 18 Months - Any
Updated: 2026-01-13
NCT04986579
Scalp Cooling in MBC
This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study intervention involved in this study is: * Paxman Scalp Cooling System
Gender: All
Ages: 18 Years - Any
Updated: 2025-11-19
1 state
NCT06215469
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
The purpose of this post-market, prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer.
Gender: All
Ages: 21 Years - Any
Updated: 2025-05-01
1 state
NCT05484973
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
The purpose of this prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer. Additionally, the purpose is also to assess the safety, tolerability and compliance, quality of life, and satisfaction with hair preservation after CT treatment.
Gender: FEMALE
Ages: 21 Years - Any
Updated: 2025-04-06
2 states
NCT05177289
Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia
This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the prevention and management of chemotherapy-induced alopecia (CIA). Therefore, we hypothesize that PBMT can reduce the severity of CIA in gynecological and breast cancer patients, increasing the patient's QoL.
Gender: FEMALE
Ages: 18 Years - Any
Updated: 2023-09-29
1 state